R

Rekah Pharmaceutical Industry Ltd
TASE:REKA

Watchlist Manager
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Watchlist
Price: 1 373 ILS -0.79% Market Closed
Market Cap: 162.5m ILS
Have any thoughts about
Rekah Pharmaceutical Industry Ltd?
Write Note

Rekah Pharmaceutical Industry Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Rekah Pharmaceutical Industry Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Revenue
â‚Ş324.4m
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
2%
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Revenue
$16.3B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
-2%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Revenue
$11.7m
CAGR 3-Years
-2%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
I
InterCure Ltd
TASE:INCR
Revenue
â‚Ş355.6m
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
45%
Mediwound Ltd
NASDAQ:MDWD
Revenue
$20.1m
CAGR 3-Years
-7%
CAGR 5-Years
-3%
CAGR 10-Years
72%
S
Seach Medical Group Ltd
TASE:SEMG
Revenue
â‚Ş162.4m
CAGR 3-Years
61%
CAGR 5-Years
66%
CAGR 10-Years
64%
No Stocks Found

Rekah Pharmaceutical Industry Ltd
Glance View

Market Cap
162.5m ILS
Industry
Pharmaceuticals

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. The firm operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The firm distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.

REKA Intrinsic Value
2 330.53 ILS
Undervaluation 41%
Intrinsic Value
Price
R

See Also

What is Rekah Pharmaceutical Industry Ltd's Revenue?
Revenue
324.4m ILS

Based on the financial report for Jun 30, 2024, Rekah Pharmaceutical Industry Ltd's Revenue amounts to 324.4m ILS.

What is Rekah Pharmaceutical Industry Ltd's Revenue growth rate?
Revenue CAGR 10Y
2%

Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Rekah Pharmaceutical Industry Ltd have been 6% over the past three years , 11% over the past five years , and 2% over the past ten years .

Back to Top